Blue Fin Capital Inc. Has $2.45 Million Position in Merck & Co., Inc. (NYSE:MRK)

Blue Fin Capital Inc. increased its holdings in Merck & Co., Inc. (NYSE:MRKGet Rating) by 0.5% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 29,844 shares of the company’s stock after purchasing an additional 141 shares during the period. Blue Fin Capital Inc.’s holdings in Merck & Co., Inc. were worth $2,448,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of MRK. Financial Avengers Inc. grew its stake in shares of Merck & Co., Inc. by 115.8% in the 4th quarter. Financial Avengers Inc. now owns 328 shares of the company’s stock valued at $25,000 after purchasing an additional 176 shares during the period. Front Row Advisors LLC lifted its holdings in shares of Merck & Co., Inc. by 89.4% during the fourth quarter. Front Row Advisors LLC now owns 339 shares of the company’s stock valued at $26,000 after acquiring an additional 160 shares during the period. Moisand Fitzgerald Tamayo LLC boosted its stake in shares of Merck & Co., Inc. by 78.0% in the 4th quarter. Moisand Fitzgerald Tamayo LLC now owns 356 shares of the company’s stock valued at $27,000 after purchasing an additional 156 shares in the last quarter. Okabena Investment Services Inc. bought a new stake in shares of Merck & Co., Inc. in the 4th quarter worth about $27,000. Finally, Western Pacific Wealth Management LP bought a new stake in shares of Merck & Co., Inc. in the 4th quarter worth about $29,000. 72.88% of the stock is owned by hedge funds and other institutional investors.

MRK opened at $89.16 on Thursday. The firm’s fifty day moving average is $88.75 and its two-hundred day moving average is $82.17. The firm has a market cap of $225.47 billion, a PE ratio of 15.95, a price-to-earnings-growth ratio of 1.19 and a beta of 0.36. Merck & Co., Inc. has a twelve month low of $70.89 and a twelve month high of $94.92. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.14 and a current ratio of 1.40.

Merck & Co., Inc. (NYSE:MRKGet Rating) last released its quarterly earnings data on Thursday, April 28th. The company reported $2.14 EPS for the quarter, beating analysts’ consensus estimates of $1.81 by $0.33. The business had revenue of $15.90 billion during the quarter, compared to analysts’ expectations of $14.64 billion. Merck & Co., Inc. had a net margin of 26.27% and a return on equity of 47.86%. The firm’s quarterly revenue was up 31.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.40 EPS. Equities analysts forecast that Merck & Co., Inc. will post 7.32 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 8th. Stockholders of record on Wednesday, June 15th will be given a dividend of $0.69 per share. This represents a $2.76 dividend on an annualized basis and a dividend yield of 3.10%. The ex-dividend date of this dividend is Tuesday, June 14th. Merck & Co., Inc.’s dividend payout ratio is currently 49.37%.

A number of research firms have recently issued reports on MRK. Mizuho initiated coverage on shares of Merck & Co., Inc. in a research note on Friday, April 1st. They issued a “buy” rating and a $100.00 target price for the company. Morgan Stanley reduced their price target on shares of Merck & Co., Inc. from $82.00 to $80.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 6th. SVB Leerink restated an “outperform” rating and issued a $102.00 price objective on shares of Merck & Co., Inc. in a research report on Monday, June 6th. Barclays boosted their target price on shares of Merck & Co., Inc. from $94.00 to $97.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 12th. Finally, StockNews.com began coverage on shares of Merck & Co., Inc. in a research note on Thursday, March 31st. They set a “strong-buy” rating on the stock. Seven analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $91.60.

Merck & Co., Inc. Profile (Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

See Also

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKGet Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.